GRPR and prostate carcinoma: We decided to investigate the potential advantages–shortcomings of the “radioligand cocktail” approach in human prostate cancer, prompted by the reported co-expression of NTS1R and GRPR in this frequently occurring cancer type [16,30,31,33,34].